Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Clark said on Monday it plans to acquire Band-Aid maker Kenvue, even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising questions about the scope of the liabilities Kimberly-Clark might inherit.

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

D.E. Shaw, one of the Tylenol-maker’s largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

The S&P 500 and Nasdaq kicked off November on firmer ground on Monday, after a slew of AI deals boosted megacap companies Amazon and Nvidia, while Kenvue shares soared after Kimberly-Clark's buyout deal.